Treatment Algorithm of Smoldering Myeloma & Newly Diagnosed Multiple Myeloma (NDMM)
From Oncology Brothers: Practice-Changing Cancer Discussions · · 22 min
This plays from the publisher's own server. We do not host a copy.
Description
Join the Oncology Brothers, in this insightful episode as they dive deep into the treatment algorithms for newly diagnosed multiple myeloma and smoldering myeloma. Featuring Gurbakhash Kaur, MD, a myeloma specialist from the Mount Sinai Hospital, the discussion covered the latest advancements in treatment options, including the recent approval of daratumumab for high-risk smoldering myeloma and the evolving landscape of frontline therapies.
In this episode, you'll learn about:
- The definition of high-risk smoldering myeloma and the criteria for treatment versus active surveillance
- The current treatment paradigms for newly diagnosed multiple myeloma, including the importance of quadruple therapy
- Insights into managing frail patients and the considerations for transplant eligibility
- The role of minimal residual disease (MRD) assessments in treatment decisions and maintenance therapy
- The impact of cytopenias and how to manage them effectively
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
- X/Twitter: https://x.com/oncbrothers
- Instagram: https://www.instagram.com/oncbrothers
- Website: https://oncbrothers.com/
Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the complexities of treating multiple myeloma. Don't miss out on this informative discussion!
#MultipleMyeloma, #SmolderingMyeloma, #HemeMalignancy, #MRD, #OncologyBrothers
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem